The LED3 hub, consisting of researchers from the Leiden Institute of Chemistry (LIC), the Institute of Biology Leiden (IBL), the Leiden Academic Centre for Drug Research (LACDR) and the Leiden Institute of Advanced Computer Science (LIACS), is very excited to organize the “LED3 Lectures”. This lecture series brings world-leading researchers in the field of early drug discovery to our university and exposes our students to the many different aspects of top science conducted in this area.
Furthermore, it strengthens the network and the active exchange of researchers across our three member institutes and, in this way, fosters interdisciplinary research at Leiden University and beyond.
Join the LED3 Lecture by Christian Hackenberger to hear about his group’s groundbreaking work on advanced chemical and chemoenzymatic strategies for site-specific protein and antibody modification. He will discuss the P5-labeling platform that his group has developed and that has redefined the synthesis of stable antibody-drug conjugates (ADCs), providing the core technology for the biotech spin-off Tubulis that he co-founded. This innovative platform recently culminated in Tubulis’ landmark $3.15 billion acquisition by Gilead, highlighting the significant impact of his work. A leader in chemical biology, Christian Hackenberger is the recipient of many awards including the Max-Bergmann Medal (2024) and the UCB-Ehrlich Award of the EFMC (2026).
The LED3 Lectures are held approximately once a month. The format is a 45 min lecture followed by a Q&A session and an informal “meet-and-greet” outside the lecture hall, in which interested participants can get in direct contact with the speakers.
